Comparative recurrence rate investigation of esomeprazole versus lansoprazole in triple-combination therapy to eradicate Helicobacter pylori infection among pediatrics: multicentre, randomized, and controlled trials

Background: Helicobacter pylori (H. pylori) infection contributes significantly to the steadily rising worldwide health burden. Due to oral and fecal-oral transmission pathways, its incidence is 50% worldwide and higher in younger individuals in underdeveloped nations. Most pediatric infections are asymptomatic or typically present as vague gastrointestinal symptoms such as persistent stomachache. Eradication therapy for H. pylori remains controversial. Only a small number of trials have compared esomeprazole with lansoprazole in children receiving triple combination therapy to eradicate H. pylori. Other treatments that have been used include bismuth, ranitidine, histamine-2 (H2) antagonists, proton pump inhibitors (PPI), and many antibiotics. This study aimed to assess the recurrence rates of esomeprazole and lansoprazole in triple combination therapy to eradicate H. pylori infection among Indonesian children. Methods: Children (those between the 2–18) hospitalized throughout the research period and suspected of having an H. pylori infection are the subjects of our multicenter, double-blind, randomized investigation. SPSS was used to process the data at a significance level of p <0.05. The factors involved were analyzed using an analytical design. This study has been registered in ClinicalTrials.gov with a trial identification number NCT05861687. Results: A total of 53 patients were eligible and met the inclusion and exclusion criteria. Four subjects were then excluded because they were lost to follow-up. A total of 51 subjects then underwent the recurrence rate of H. pylori infection analysis. It shows that after 90 days of post-short-term treatment, there was no significant difference (p=1.000). Conclusion: There was no significant difference in the recurrence rate of children with H. pylori infection when using esomeprazole or lansoprazole.